Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
By J. Cassidy, S. Clarke, E. Díaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T-S. Yang, F. Rivera and 3 more. Journal of Clinical Oncology, 2008
808 citations recorded by the source corpus.
Subfields: Oncology
View Paper: https://www.semanticscholar.org/paper/d9f8d1455a05a1dc1df53fd0369d0387b3d125ea
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, background): “The TRI‑ COLORE trial, a phase III trial conducted in Japan, compared the efficacy and safety of S‑1 + IRI + BEV with FOLFOX + BEV or CAPOX + BEV as first‑line therapy for PS 0–1 patients with unresectable colorectal cancer.”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, neutral): “(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient ”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (2011, neutral): “(1) FOLFOX(4) [30, 31] ± bevacizumab [32], CapeOX(5) ±bevacizumab [32, 33].”
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “The oral fluoropyrimidine capecitabine can be used as an alternative to 5-FU/leucovorin alone [238] and in combination with oxaliplatin [239].”
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, neutral): “5-FU/LV [4, 5].”